CD109 and cancer: As treatment with our two anti-CD109 mAbs did not affect the proliferation or migration of CD109 overexpressing cancer cell lines, further investigations are warranted to determine the therapeutic potential of the humanised IgG1 or the conjugated versions of such antibodies, for use in targeted therapy of tumours with CD109 overexpression.